EPT-17 PHASE I STUDY OF BRAF INHIBITOR (VEMURAFENIB) IN COMBINATION WITH THE MTOR INHIBITOR (EVEROLIMUS) IN BRAF(V600E) POSITIVE CHILDHOOD AND AYA BRAIN TUMORS

Lignende værker

• Dual inhibition of BRAF and mTOR in BRAF(V600E)-mutant pediatric, adolescent, and young adult brain tumors
  af: Sen, Shiraj, et al.
  Udgivet: (2020)
• Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies
  af: Subbiah, Vivek, et al.
  Udgivet: (2018)
• BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
  af: Del Bufalo, Francesca, et al.
  Udgivet: (2018)
• EPT-05 BRAFv600E INHIBITOR (VEMURAFENIB) IN PEDIATRIC PATIENTS AFFECTED BY BRAFv600E MUTATED GLIOMAS
  af: del Bufalo, Francesca, et al.
  Udgivet: (2016)
• Successful treatment of a BRAF V600E-mutant extracranial metastatic anaplastic oligoastrocytoma with vemurafenib and everolimus
  af: Shi, Liangliang, et al.
  Udgivet: (2018)